文献速递细菌感染、耐药与抗菌药物医院感染防控

资源有限地区耐药分子检测的影响与成本建模

Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings.
PubMed 文献 · Clin Infect Dis · 2026-01-01

研究建模了资源有限地区住院血流感染患者中,培养依赖的病原鉴定与耐药分子检测对比标准诊疗的影响。在100%诊断覆盖、更短培养周转时间和高耐药流行率下,分子检测最多可减少6%死亡、5%住院日和21%不适当抗生素治疗天数。每次分子检测的最低抵消成本从印度109美元到南非585美元不等。

要点

  • 在100%诊断覆盖、短周转时间和高耐药率下,分子检测最多减少6%死亡。
  • 分子检测最多减少5%住院日和21%不适当抗生素治疗天数。
  • 抵消节省后每次分子检测最低成本:印度109美元至南非585美元。

核心结论

  • 在高耐药负担且血培养基础设施支持快速周转的环境中,分子检测可改善血流感染患者健康结局。
  • 其影响受周转时间延迟和经验性治疗有效性限制。
  • 以100美元或更低成本实施分子诊断可产生医疗系统成本节省,支持其采用以改善健康结局和减少耐药,同时保持成本中性。

研究设计与样本

  • 建模研究,评估培养依赖的分子检测用于住院血流感染患者的病原鉴定和耐药检测。
  • 比较标准诊疗(经验性治疗、血培养、表型药敏试验)与分子诊断,变化培养和药敏覆盖、培养周转时间和耐药流行率。

主要发现

  • 分子检测的最大影响出现在100%诊断覆盖、更短培养周转时间和高耐药流行率时。
  • 在此条件下,最多减少6%死亡(IQR 0%-12.1%)。
  • 最多减少5%住院日(IQR 0.1%-10.7%)。
  • 最多减少21%不适当抗生素治疗天数(IQR 18.2%-24.4%)。
  • 在所有建模场景中,抵消节省后每次分子检测的最低成本从印度109美元到南非585美元不等。

关键数值与推荐

  • 100%诊断覆盖、更短培养周转时间、高耐药流行率条件下,死亡减少最多6%(IQR 0%-12.1%)。
  • 住院日减少最多5%(IQR 0.1%-10.7%)。
  • 不适当抗生素治疗天数减少最多21%(IQR 18.2%-24.4%)。
  • 每次分子检测最低抵消成本:印度109美元至南非585美元。

临床怎么用

  • 在高耐药负担且血培养基础设施支持快速周转的环境中,可考虑实施培养依赖的分子检测以改善血流感染结局。
  • 以100美元或更低成本实施分子诊断可产生医疗系统成本节省并保持成本中性。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited diagnostic access in resource-limited settings contributes to poor health outcomes among bacterial sepsis patients and the spread of antimicrobial resistance (AMR). Molecular diagnostic profiling of AMR may enable faster targeting of antibiotic therapies, improving clinical outcomes, reducing AMR development, and saving costs. METHODS: We modeled the impact of a culture-dependent molecular test for pathogen identification and resistance testing among hospitalized bloodstream infection patients to guide effective and cost-efficient implementation of these tools. We evaluated patient mortality, antibiotic use, hospital-associated infections, hospital days, and costs under the standard of care (empiric therapy, blood culture, phenotypic susceptibility testing) compared with molecular diagnostics by varying culture and susceptibility testing coverage, culture turnaround time, and AMR prevalence. RESULTS: The greatest impact of the molecular test occurred with 100% diagnostic coverage, shorter culture turnaround time, and high AMR prevalence, reducing up to 6% of deaths (interquartile range [IQR], 0%-12.1%), 5% of hospital days (IQR, 0.1%-10.7%), and 21% of days on inappropriate antibiotic therapy (IQR, 18.2%-24.4%). The minimum cost per molecular test performed, offset by cost savings, ranged from $109 in India to $585 in South Africa across all modeled scenarios. CONCLUSIONS: In high AMR burden settings with blood culture infrastructure supporting fast turnaround times, a molecular test could improve health outcomes of bloodstream infection. Impact is limited by delayed turnaround times and the effectiveness of empiric therapy. Molecular diagnostics implemented at $100 or less can generate healthcare-system cost savings, supporting their adoption to improve health outcomes and reduce AMR while remaining cost-neutral.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Chevalier JM, Hansen MA, Blumel B, et al. Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings. Clin Infect Dis. 2026. PMID: 40350685. doi:10.1093/cid/ciaf236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。